Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Pharmacology > GPCR 2 > Flashcards

GPCR 2 Flashcards

1
Q

What types of post translational regulation of G protein dependent signalling exist?

A

Receptor phosphorylation
G protein phosphorylation
Effector phosphorylation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How does post translational regulation alter the outcome?

A

By altering any of those aspects you alter the protein activity and the signalling pathway

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What happens when GPCR are phosphorylated by second messenger activated protein kinases?

A

Negative feedback mechanism on pathway activation
Heterologous desensitisation of neighbours
Influences affinity, efficacy of agonist receptor complex
Alters G protein selectivity
Can happen in the absence of an agonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What happens when GPCR are phosphorylated by GPCR kinases (GRKs)?

A

Homologous desensitisation -
Arrestins bind to phosphorylated receptors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is homologous desensitisation?

A

GPCR regulation phosphorylation by GRKs
only happens when activated by an agonist as the change in shape reveals the phosphorylation sites

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What happens when arrestins bind to phosphorylated receptors?

A

Prevent G protein interaction
Desensitisation/ internalisation via clathrin pits
Followed by dephosphorylation
Activate non G protein dependent signalling pathways

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Describe internal signalling

A

Persistent responses (every 30 mins)
Different sub cellular environment to cell surface
Will influence the effector and response
Receptor will remain active until late endosomal trafficking
Eventual resensitisation and return to the surface

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the targets of physiological regulation of G proteins at the mRNA level?

A

Receptor
G protein
Effector proteins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What sort of pathways are affected by transcriptional regulation of G proteins?

A

Thyroid hormone
Glucocorticoids
Sex hormones
Cyclic AMP
Puberty
Menopause
Endocrine disorders

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What happens due to ‘gain of function’ mutations in G protein linked signalling during diseases at the receptor level?

A

Receptor proteins become constitutively active in absence of agonist
Some compensation by reduced receptor expression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What happens due to ‘loss of function’ mutations in G protein linked signalling during diseases at the receptor level?

A

Loss of receptor transcription/ translation
Inappropriate sub cellular targeting
Abnormal receptor proteins
Altered affinity/ efficacy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What happens due to ‘gain of function’ mutations in G protein linked signalling during diseases at the G protein level?

A

Causes a loss of GTPase activity
Constitutive activation in the absence of agonist receptor involvement

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What happens due to ‘loss of function’ mutations in G protein linked signalling during diseases at the G protein level?

A

Loss of G protein transcription/ translation
Inappropriate sub cellular targeting
Abnormal forms of G protein

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the receptor gain of function mutations?

A

LH - familial make precocious puberty
TSH - toxic thyroid hyperplasia/ adenoma
PTH - Jansen’s chondrodysplasia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the receptor loss of function mutations?

A

V2 - nephrogenic disbetes insipidus
ACTH - glucocorticoid deficiency
TP - congenital bleeding
ET;B - aganglionic megacolon

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the G protein gain of function mutation?

A

G alpha s - thyroid adenoma, cardiomyopathy, McCune-Albright syndrome
G alpha q - cardiac hypertrophy decompensation to failure
G alpha t - stationary night blindness

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What are the G protein loss of function mutation?

A

G alpha s - pseudohypoparathyroidism
G alpha i2 - ulcerative colitis and adenocarcinoma of the colon, type ll diabetes
G alpha q - obesity, impaired lipolysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What are RGS proteins?

A

Multifunctional GTPase accelerating protein that promote GTP hydrolysis by the alpha sub unit of heterotrimeric G proteins

19
Q

How does phosphorylation affect RGS proteins?

A

Can increase or decrease RGS activity or influence translocation to / interaction with membrane
Influences RGS stability / rate of degradation

20
Q

How do is RGS activity affected by palmitoylation?

A

Reversible palmitoylation or lipid modification promotes membrane association
Increases RGS activity

21
Q

How are RGS proteins orientated?

A

Sequences in receptor proteins help localise and orientate RGS proteins towards G proteins

22
Q

What influences RGS protein expression?

A

2nd messenger pathways
Transcription factors (PKA, PKC)
Disease
Drugs of addiction

23
Q

Give some examples of recent development in GPCR research

A

Agonist trafficking / functional selectivity
Allosteric regulation
GPCR oligomerisation
Other accessory proteins
Orphan GPCRs - approaches to identify

24
Q

What are the factors of agonist trafficking and functional selectivity?

A

Multiple receptor activation states possible
Different agonists cause different conformational changes
Some antagonists only block subsets of agonist induced signalling events at same receptor

25
Q

Describe the multiple receptor activation state factor

A

Agonist increase the proportion of receptors in various active conformations / associated with various signalling pathways (pluri-dimensional)
Natural agonist ligands have potential to activate all possible pathways depending on context

26
Q

Describe the different agonists cause different conformations factor

A

Increase or decrease favourable interactions with specific G proteins and extent of activation of various signalling pathways
Conformations differ in susceptibility to desensitisation
TRV130 biased agonist against mu opioid receptor - retains analgesia but reduced side effects than morphine

27
Q

Explain the some antagonist only block subsets of agonist pathways factor

A

Increases drug specificity
Decreases side effects

28
Q

What is an orthosteric site?

A

The ligand / agonist binding site

29
Q

What is an Allosteric site and why do molecules bind here?

A

Allosteric sites can be intracellular or extracellular
Any molecule of appropriate size to influence the orthosteric site without actually binding there

30
Q

Describe some of the novel drugs that may act at Allosteric sites

A

They will modify responses to various orthosteric ligands
They will be small and less complex ligands
Less complex binding interactions
Smaller, saturable effects
May display bias for some signalling events
Greater distinction between receptor subtypes that orthosteric ligands

31
Q

Name some of the benefits of novel drugs acting at Allosteric sites

A

Fewer side effects
Safer in the case of overdose
Positive allosteric regulators display less desensitisation phenomena vs orthosteric agonists
Potential for pathway dependant allosteric modulation

32
Q

What is maraviroc?

A

Novel antiretroviral for HIV
A negative allosteric regulator of CCR5 chemokine receptors on the surface of CD4+ cells
Prevents binding and entry of HIV

33
Q

What is palonosetron?

A

A novel Allosteric antagonist at serotonin 5-HT3 receptors
Used for anti-emetic therapy

34
Q

What is oligomerisation?

A

A chemical process that converts monomers to macro molecular complexes through a finite degree of polymerisation

35
Q

How does GPCR oligomerisation afford greater diversity?

A

There are doing hot 900 GPCRs?

36
Q

What are the implications for GPCR oligomerisation?

A

Transport to the cell surface
Ligand binding
Receptor activation
G protein coupling
Assymetrical binding of RGS proteins
Receptor desensitisation
Disease

37
Q

Explain the implication of transport to the cell surface membrane

A

Masks sequences for ER retention by gate keeper proteins
Needed to enable receptors to pass quality control

38
Q

Explain the implication of ligand binding

A

Both partners contribute to novel binding site
Binding of agonist/ antagonist to one partner influences binding profile of other
E.G binding of D3 agonist increases affinity of agonists for D1

39
Q

Explain the implication of G protein coupling

A

2 receptors per G protein - do both need to be activated?
Cis or trans activation depending on which receptor G protein is physically closest to

40
Q

Give an example of how heteromer specific signalling is characterised

A

Monoclonal antibodies can be generated that specifically recognise receptor heteromers but not homomers

41
Q

Describe the GPCR recent development including accessory proteins

A

Similar consequences to dimerisation but the protein is not a GPCR

42
Q

What are orphan GPCRs?

A

100-200 GPCRs with no known ligand or function identified by sequencing human genomes

43
Q

How can orphan GOCRs be identified?

A

Using bioinformatics to predict candidate ligands based on comparisons with known sequences and structures

Pharmacology (18 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions